Promoting the Effector Function of Natural Killer (NK) Cells with a Focus on Bispecific Redirecting Antibodies

Pouya  Safarzadeh Kozani; Pooria Safarzadeh Kozani; Abdolkarim Sheikhi

doi:10.5812/tms.119095

Promoting the Effector Function of Natural Killer (NK) Cells with a Focus on Bispecific Redirecting Antibodies

authors:

Pouya Safarzadeh Kozani ¹ , Pooria Safarzadeh Kozani ² , Abdolkarim Sheikhi ^{3
, *}

1 Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran

2 Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

3 Department of Immunology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran

Trends in Medical Sciences: Vol.1, issue 3; e119095

published online: September 18, 2021

article type: Letter

received: August 28, 2021

accepted: August 31, 2021

DOI: https://doi.org/10.5812/tms.119095

how to cite: Safarzadeh Kozani P , Safarzadeh Kozani P, Sheikhi A. Promoting the Effector Function of Natural Killer (NK) Cells with a Focus on Bispecific Redirecting Antibodies. J Adv Immunopharmacol. 2021;1(3):e119095. https://doi.org/10.5812/tms.119095.

Keywords

NK Cells Tumor Immunotherapy Bispecific Nanobody (VHH)

Footnotes

Authors' Contribution: PSKs structured, wrote, and revised the manuscript. AS planned, structured, and contributed to the writing and revision of the manuscript.
Conflict of Interests: There is no conflict of interest.
Ethical Approval: The ethical code was IR.DUMS.REC.1400.006.
Funding/Support: This study was supported by the Dezful University of Medical Sciences.

References

1.
Toffoli EC, Sheikhi A, Hoppner YD, de Kok P, Yazdanpanah-Samani M, Spanholtz J, et al. Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers (Basel). 2021;13(4). [PubMed ID: 33572396]. [PubMed Central ID: PMC7916216]. https://doi.org/10.3390/cancers13040711.
2.
Yoon MS, Pham CT, Phan MT, Shin DJ, Jang YY, Park MH, et al. Irradiation of breast cancer cells enhances CXCL16 ligand expression and induces the migration of natural killer cells expressing the CXCR6 receptor. Cytotherapy. 2016;18(12):1532-42. [PubMed ID: 27720639]. https://doi.org/10.1016/j.jcyt.2016.08.006.
3.
Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941-4. [PubMed ID: 19509221]. https://doi.org/10.1158/0008-5472.CAN-09-0547.
4.
Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14(1):75. [PubMed ID: 33941237]. [PubMed Central ID: PMC8091790]. https://doi.org/10.1186/s13045-021-01084-4.
5.
Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250. [PubMed ID: 22474489]. [PubMed Central ID: PMC3312285]. https://doi.org/10.1155/2012/980250.
6.
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Novel antigens of CAR T cell therapy: New roads; old destination. Transl Oncol. 2021;14(7):101079. [PubMed ID: 33862524]. [PubMed Central ID: PMC8065293]. https://doi.org/10.1016/j.tranon.2021.101079.
7.
Safarzadeh Kozani P, Safarzadeh Kozani P, O'Connor RS. In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL. Mol Cancer Ther. 2021;20(7):1223-33. [PubMed ID: 33903140]. [PubMed Central ID: PMC8285067]. https://doi.org/10.1158/1535-7163.MCT-20-1089.
8.
Bever CS, Dong JX, Vasylieva N, Barnych B, Cui Y, Xu ZL, et al. VHH antibodies: emerging reagents for the analysis of environmental chemicals. Anal Bioanal Chem. 2016;408(22):5985-6002. [PubMed ID: 27209591]. [PubMed Central ID: PMC4983233]. https://doi.org/10.1007/s00216-016-9585-x.
9.
Sheikhi A, Hojjat-Farsangi M. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein. Hum Vaccin Immunother. 2021;17(1):92-7. [PubMed ID: 32663051]. [PubMed Central ID: PMC7872019]. https://doi.org/10.1080/21645515.2020.1787066.

comments